TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00152269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 10mg Tablet, oral Daily for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 25mg Tablet, oral Daily for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, Tablet, oral Daily for 12 months
Study: NCT04006275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonovue and Sonazoid
Description: Subjects were randomized to receive SonoVue firstly and Sonazid secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at our department for at least 30min.~contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonazoid and Sonovue
Description: Subjects were randomized to receive Sonazoid firstly and SonoVue secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at our department for at least 30min.~contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio.
Study: NCT02036853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triheptanoin
Description: Schedule A: Subjects previously treated with triheptanoin will continue to dose at approximately 35% of total daily calories (\~1-4g/kg/day, depending on age).~Schedule B: Subjects who are naïve to triheptanoin will begin a 2-week fixed titration schedule up until they have reached 35% of total daily calories (\~1-4 g/kg/day depending on age). If a subject has not reached the target of 35% of total daily calories, by the end of the 2-week fixed titration period, dose titration should continue until achieved or until the maximally tolerated dose has been established.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triheptanoin
Description: Schedule A: Subjects previously treated with triheptanoin will continue to dose at approximately 35% of total daily calories (\~1-4g/kg/day, depending on age).~Schedule B: Subjects who are naïve to triheptanoin will begin a 2-week fixed titration schedule up until they have reached 35% of total daily calories (\~1-4 g/kg/day depending on age). If a subject has not reached the target of 35% of total daily calories, by the end of the 2-week fixed titration period, dose titration should continue until achieved or until the maximally tolerated dose has been established.
Study: NCT01629446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine hydrochloride
Description: Single Dose = Solution containing 400 μg lofexidine HCl and a tracer amount of 14C lofexidine
Study: NCT03497351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicardipine
Description: The patients in Group N were infused the 130/0.4 hydroxyethyl starch and sodium chloride injection ( 7 ml/kg, 0.4 ml/kg/min) after anesthesi induction and before skin incision. Then the HR, SAP, DAP, MAP, CO, CI, SV, SVI, PPV and SVV were recorded. When the circulation was stability, Nicardipine was given, and the the 130/0.4 hydroxyethyl starch and sodium chloride injection was infused again.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urapidil
Description: The patients in Group N were infused the 130/0.4 hydroxyethyl starch and sodium chloride injection ( 7 ml/kg, 0.4 ml/kg/min) after anesthesi induction and before skin incision. Then the HR, SAP, DAP, MAP, CO, CI, SV, SVI, PPV and SVV were recorded. When the circulation was stability, Urapidil was given, and the the 130/0.4 hydroxyethyl starch and sodium chloride injection was infused again.
Study: NCT01563133

Intervention type: PROCEDURE
Group type: OTHER
Intervention: EUS-FNA
Description: Endoscopic ultrasound fine needle aspiration: ultrasound endoscopy of a lesion with aspiration of the lesion fluid through a needle

Intervention type: DEVICE
Group type: OTHER
Intervention: nCLE
Description: needle-based Confocal Laser Endomicroscopy
Study: NCT04423341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol Oral Solution [Epidiolex]
Description: 100 mg BID for three months Placebo oral solution for three months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol Oral Solution [Epidiolex]
Description: 100 mg BID for three months Placebo oral solution for three months
Study: NCT03415711

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3®
Description: VSL#3® 450 billion sachets

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3®
Description: VSL#3® 450 billion sachets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine
Description: Mesalamine 2.4 g/day in once daily administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine
Description: Mesalamine 2.4 g/day in once daily administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine
Description: Mesalamine 2.4 g/day in once daily administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: sachets with maltose, cornstarch and dioxide
Study: NCT01638182

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 27 participants received for three months 1 placebo capsule per day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K1-capsules
Description: 27 participants received for 3 months 1 vitamin K1-capsule per day containing 52 µg of K1/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K2-capsules
Description: 27 participants received for 3 months 1 vitamin K2-capsule per day containing 75 µg of MK-7.
Study: NCT02246465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXI-109
Study: NCT04609644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Tools for Asthma Self-Management
Description: Please see description of active study arm.
Study: NCT02762370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 32 mg
Description: Single 5 mL IA injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCA IR 40 mg
Description: Single 1 mL IA injection
Study: NCT03572608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Description: Classical acupuncture points will be used without a formal traditional Chinese medicine diagnosis in the intervention group. Neither manual needle stimulation nor moxibustion will used. The needles will left in place for 30 min and de qi was not sought. The points will be selected bilateral Heart-7, bilateral Large Intestine-4, Governing Vessel-20 and ear shenmen for the first session. Bilateral Conception Vessel-3,4,6, bilateral Liver-3, bilateral Stomach-30, bilateral Spleen-6, bilateral Governing Vessel-20 will be used for the second session. Bilateral Large Intestine-4, bilateral Spleen-6,9, bilateral Stomach-36 will be used for the last session. All acupuncture points will be selected and localized on the basis of the WHO Standardised Acupuncture Point Location.
Study: NCT05589558

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: consequently performed 4 biopsy methods (TRUS-guided biopsy, cognitive, fusion and transperineal template mapping biopsy)
Description: TRUS-guided biopsy - extensive number of biopsies taken transrectally involving peripheral and transitional zones (8-12 cores); cognitive biopsy - targeted biopsy with MRI information and TRUS guidance but without fusion technology (2-4 cores); fusion biopsy - targeted biopsy with MRI information using MRI/TRUS fusion technology (2-4 core); transperineal template mapping biopsy - systematic transperineal TRUS-guided biopsy with special template use to aid accurate placement of biopsy needles (more than 20 cores).
Study: NCT00246740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Periostat
Description: In addition to standard care, patients received oral administration of 20 mg of doxycycline twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: In addition to standard care, patients received oral administration of placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.
Study: NCT00528697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: Subjects will take 0.5 and 1 and/or 5 and/or 10 mg ABT-089 tablets (actual dose based on weight) once daily for 8 weeks.
Study: NCT02398591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 53718678
Description: JNJ 53718678 will be orally administered once in a dose of 250, 500 or 1000 mg on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 53718678
Description: JNJ 53718678 will be orally administered once in a dose of 250, 500 or 1000 mg on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to JNJ 53718678 will be orally administered once on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to JNJ 53718678 will be orally administered once on Day 1.
Study: NCT00528697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: Subjects will take 0.5 and 1 and/or 5 and/or 10 mg ABT-089 tablets (actual dose based on weight) once daily for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: Subjects will take 0.5 and 1 and/or 5 and/or 10 mg ABT-089 tablets (actual dose based on weight) once daily for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: Subjects will take 0.5 and 1 and/or 5 and/or 10 mg ABT-089 tablets (actual dose based on weight) once daily for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atomoxetine
Description: Subjects will take 10, and/or 18 and/or 25 mg atomoxetine tablets once daily for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subject will take a tablet once daily for 8 weeks
Study: NCT00522899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 1
Description: Aerobic exercise plus computer-based mental activity training: both 3 days/week, 60 minutes/session for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 1
Description: Aerobic exercise plus computer-based mental activity training: both 3 days/week, 60 minutes/session for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 2
Description: Aerobic exercise plus educational DVDs: both 3 days/week, 60 minutes/session for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group 2
Description: Aerobic exercise plus educational DVDs: both 3 days/week, 60 minutes/session for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 3
Description: Stretching/toning exercise group plus computer-based mental activity training: both 3 days/week, 60 minutes/session for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group 3
Description: Stretching/toning exercise group plus computer-based mental activity training: both 3 days/week, 60 minutes/session for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group 4
Description: Stretching/toning exercise group plus educational DVDs: both 3 days/week, 60 minutes/session for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group 4
Description: Stretching/toning exercise group plus educational DVDs: both 3 days/week, 60 minutes/session for 12 weeks.
Study: NCT02398591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to JNJ 53718678 will be orally administered once on Day 1.
Study: NCT00548496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-751689
Description: SB-751689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match
Study: NCT01212302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimizing ASA and clopidogrel treatment
Description: ASA 100 mg, ASA 300 mg, ASA 500 mg~Clopidogrel 75 mg, Clopidogrel 150 mg, Ticlopidine 2x 250 mg, Prasugrel 10 mg. Intervention List:~In the case of clopidogrel low-response, the maintenance dose was doubled (repeated loading dose followed by 150 mg daily), and when still ineffective ticlopidine or prasugrel, if available and not contraindicated, were used. ASA low-responders were treated by increasing the dose to 300 mg in a first step or to 500 mg ASA when the first modification was not sufficient.
Study: NCT04212676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body Awareness Therapy
Description: The BAT for the participants was based on the works of Roxendal and Dropsy. Activities include relaxation exercises, breathing exercises, floor exercises for trunk and pelvic movements, weight transfer using extremities and proprioceptive movements. Movements will be made in various positions to determine the centerline of the body. All exercises will be started in the supine position to maximize proprioceptive motion feedback and minimize energy requirements during tasks. Movements will be taught in a series of lessons over a period of 8 weeks with advance advancement of selected movements depending on participant comfort.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: Diaphragmatic breathing exercise Thoracic expansion exercises (Chest breathing and bilateral segmental breathing exercises) Inductive spirometry (Triflo®) exercise Cough development techniques

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Diaphragmatic breathing exercise Thoracic expansion exercises (Chest breathing and bilateral segmental breathing exercises) Inductive spirometry (Triflo®) exercise Cough development techniques
Study: NCT01710449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perfluorinated gas/oxygen mixture
Description: Subjects are imaged with MRI one time in an proof of concept study for the use of perfluorinated gas / oxygen mixtures as an MRI contrast agent for lung function.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perfluorinated gas/oxygen mixture
Description: Subjects are imaged with MRI one time in an proof of concept study for the use of perfluorinated gas / oxygen mixtures as an MRI contrast agent for lung function.
Study: NCT03233321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry cold application
Description: Dry cold application using ice bag (Crushed ice was filled in ice bag with ½ table spoon of salt and then covered by clean linen to prevent moisture) was placed over the injection site for about 20 minutes.
Study: NCT01227330

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication adherence intervention
Description: 12-week behavioral feedback intervention to improve adherence to statin medication

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention-control
Description: Health education visits that are unrelated to medications or cholesterol, provided on the same visit schedule as the intervention group
Study: NCT04858165

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MY GERYFS PROTOCOL
Description: The MY GERYFS will be introduced through a guideline document, dissemination through the department of nursing, notices on the intranet and provision of large signs indicating that MY GERYFS are in progress and the times of meals for each ward. The developed protocol in phase 1 and 2 will be tested in single-centre in a before and after study for its feasibility and safety. In the pre-study, patients will be given usual care. In the post-study, patients will care according to the developed protocol. Clinical outcomes such as malnutrition risk, medical background, anthropometry data, nutrition-focused physical findings, dietary intake, mealtime barrier, Hospital Foodservices satisfaction will be recorded.
Study: NCT03311711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPIRIT-in person
Description: The SPIRIT-in person intervention adapted for dementia will include one session and will be conducted in a private room at the clinic. SPIRIT is a structured psychoeducational intervention, targeting both patient and surrogate. The SPIRIT intervention assists patients in clarifying their end-of-life preferences and helps surrogates understand the patient's wishes and prepare for the surrogate role. The intervention is expected to last 45-60 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPIRIT-remote
Description: The SPIRIT-remote intervention adapted for dementia will include one session and will be conducted through teleconference. SPIRIT is a structured psychoeducational intervention, targeting both patient and surrogate. The SPIRIT intervention assists patients in clarifying their end-of-life preferences and helps surrogates understand the patient's wishes and prepare for the surrogate role. The intervention is expected to last 45-60 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will receive the usual care that is provided through the clinic they receive care through. This may include completing advanced directives, referral to a support group, or referral to a social worker for further discussion about end of life issues.
Study: NCT03233321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sub cutaneous injection (low molecular weight heparin)
Description: sub cutaneous injection (low molecular weight heparin) has been administered on injection site
Study: NCT03145688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Physical Activity Planning
Description: Families will receive the same guidelines as the standard education control group but will also be provided with family physical activity planning material. This material will include a skill training content workbook on how to plan for family physical activity. The material includes a brainstorming exercise for parents where they list physical activities they think their children have found fun in the past, as well as activities that they would find enjoyable to do as a family. We will provide this material as prompts/suggestions. Families will be instructed to plan for when, where, how, and what physical activity will be performed \& then track their physical activity. These aspects will be re-introduced and discussed at week 6 and week 12 in booster sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Physical Activity Habit Formation
Description: Families will receive the same content as the education control condition and the physical activity planning condition but with additional material on creating physical activity support habits. A key component of the habit section will be based on planning for context-dependent repetition, with pointers on how to maintain repetition as habit forms. The importance of creating cues for parental support of child physical activity is then outlined. Cues will also be considered factors that a) can precede the support activity but b) not be present very often when the activity is not to be performed. We will suggest that cues that have repeated exposure during times when family physical activity is not present Parents will then be asked to brainstorm and create a plan of consistency and cues with the workbooks provided. These aspects will be re-introduced and discussed at week 6 and week 12 in booster sessions.
Study: NCT00725062

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD4+CD25+ regulatory T cells
Description: Cohort 1 will receive 3 x 10\^6 CD4+CD25+ cells/kg, Cohort 2 will receive 1 x 10\^7 CD4+CD25+ cells/kg, Cohort 3 will receive 3 x 10\^7 CD4+CD25 cells/kg

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Occurs on Day 0 of study - HLA-identical sibling donor peripheral blood progenitor cell (PBPC) transplantation
Study: NCT01656265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 197
Description: Daily repeating dose of oral ARQ 197, twice a day just after meals. Dose of ARQ 197 will be escalated according to 3+3 rule.
Study: NCT03195309

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Compare different concentration of ropivacaine and fentanyl for elective Cesarean delivery post operative pain control.
Study: NCT01724658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate
Description: testosterone undecanoate 40 mg orally twice a week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo orally twice a week with progynova 1 mg oral daily
Study: NCT01401634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral water
Description: 2 Liters of water given orally

Intervention type: OTHER
Group type: OTHER
Intervention: Intravenous normal saline
Description: 2 Liters Intravenous normal saline
Study: NCT03638232

Intervention type: OTHER
Intervention: Administrative data
Description: Gender Birthdate Department and town of residence Date of death Affiliation to french Universal Health Coverage

Intervention type: OTHER
Intervention: Medical data
Description: Long term affection code, number and medical codification Date of onset and end of care Codification of medical acts and consultation (With common classification of medical acts)

Intervention type: OTHER
Intervention: Drug exposition data
Description: Speciality of prescribing physician CIP code of drug Name of speciality prescribed Date of deliverance Date of prescription Number of treatment box delivered
Study: NCT02079987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ED-to-home care transition intervention
Description: The Area Agency on Aging coach's role is to build self-management capabilities for the patient and their caregiver. During each contact, the coach reviews the four components of the Care Transition Intervention: 1: Follow-up Medical Visit. 2: Knowledge of Red Flag Symptoms. 3: Medication Reconciliation. 4: The Personal Health Record (PHR). The coach assists patients use the PHR to document and maintain vital information and to communicate with providers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Patients randomized to usual care will receive verbal and written discharge instructions from the treating ED physician and nurse as is the standard of care.
Study: NCT03428178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAAV2-ND4
Description: rAAV2-ND4 of vitreous cavity injection
Study: NCT03147729

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiofrequency non ablation
Description: Use of radiofrequency